Liraglutide treatment in children with obesity

IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-10-15 DOI:10.1038/s41575-024-01010-2
Eleni Kotsiliti
{"title":"Liraglutide treatment in children with obesity","authors":"Eleni Kotsiliti","doi":"10.1038/s41575-024-01010-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 12","pages":"829-829"},"PeriodicalIF":45.9000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41575-024-01010-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利拉鲁肽治疗儿童肥胖症
一项IIIa期试验测试了利拉鲁肽(一种胰高血糖素样肽1受体激动剂)对82名肥胖症儿童(6至12岁)的安全性和有效性。这些儿童被随机分配(2:1)接受每日剂量为3毫克的利拉鲁肽(或最大耐受剂量)或安慰剂,并接受生活方式干预。第56周达到了主要终点,即体重指数(BMI)与基线相比的百分比变化:利拉鲁肽组的平均BMI百分比变化为-5.8%,而安慰剂组为1.6%(95% CI -11.6至-3.2,P< 0.001)。次要终点是体重指数下降至少 5%,接受利拉鲁肽治疗的儿童中 46%、安慰剂组中 9%(调整后的几率比 6.3,95% CI 1.4-28.8,P = 0.02)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
52.30
自引率
0.60%
发文量
147
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.
期刊最新文献
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract The ins and outs of tumour resistance Non-canonical metastatic colorectal cancer Unlocking CD8+ T cell potential in chronic hepatitis B virus infection. High-density lipoprotein lipidome: a neglected source of hepatic lipids
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1